Healthcare Industry News: dihydroergotamine
News Release - June 26, 2007
MAP Pharmaceuticals Appoints Bernard J. Kelley to Board of DirectorsMOUNTAIN VIEW, Calif., June 26 (HSMN NewsFeed) -- MAP Pharmaceuticals, Inc. today announced the appointment of Bernard J. Kelley to the company's Board of Directors.
Mr. Kelley retired from Merck and Co. Inc. in 2003, after more than 35 years of service to the company. Most recently, Mr. Kelley was a member of the Merck Management Committee, reporting to the Chairman, President and CEO of Merck, and served as President of the Merck Manufacturing Division. In his capacity as President of the Manufacturing Division, Mr. Kelley had responsibility for chemical, pharmaceutical and biological manufacturing at 30 facilities in 17 countries around the world employing over 17,000 people. Additionally, he directed the activities of corporate engineering, global procurement and Merck's strategic Operational Excellence Initiative.
"Bernie is an important addition to the team as he brings over 35 years of successful pharmaceutical strategic and general management, manufacturing and commercial product experience to MAP Pharmaceuticals. His leadership and broad operational experience will be particularly helpful to the company as we advance our lead product candidates through clinical development and, if successful, into commercial pharmaceutical operations for the treatment of pediatric asthma and migraine," said Timothy S. Nelson, President and CEO of MAP Pharmaceuticals.
Mr. Kelley's experience at Merck includes positions of increasing responsibility throughout his career, including over nine years as President of the Merck Manufacturing Division, and Senior Vice President of Operations. Mr. Kelley became Vice President of Business Affairs for Merck's Agricultural and Veterinary Division after three years of service as President of a Merck subsidiary and numerous management and operational roles in the agricultural and veterinary division.
Mr. Kelley received an engineering degree from the U.S. Naval Academy and served in the United States Navy. He has served on the Supervisory Board of Aventis Pasteur-MSD, France, the Board of Directors of Merial Limited, U.K., the Board of Directors, N.J. Chamber of Commerce and the Board and Executive Committee of the National Association of Manufacturers. Currently, Mr. Kelley is a member of the Board of Directors of Codexis, Inc.
About MAP Pharmaceuticals
Located in Mountain View, California, MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities, including the two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraines. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
Source: MAP Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.